Named-patient program vs. personal importation: how they differ.

Two different pathways bring a foreign-sourced medicine to a patient in a country where the medicine is not locally registered or not locally available. The first is the named-patient program, a structured pathway in which a treating physician obtains a specific therapy for a specific patient through a regulatory-recognized channel. The second is personal importation, a more informal pathway in which a patient, typically with or without a prescription, imports a small quantity of a medicine for their own use. Both are real. Both are regulated. They differ in ways that matter to families, prescribers, and receiving institutions, and this page sets those differences out in plain English.

The named-patient pathway

A named-patient program is a pathway in which a destination country's health authority permits the importation of a specific, unregistered, or locally-unavailable medicine for a specific, identified patient under a treating physician's prescription. The pathway is structured. A treating prescriber determines the therapy is medically necessary and documents the determination; a regulatory application is filed, either by the prescriber or by a coordinating pharmacy acting on the prescriber's instruction; the destination health authority reviews and, if appropriate, authorizes the importation; the medicine is sourced and shipped under a documented chain of custody; the medicine is dispensed under the prescriber's care; and an adverse-event reporting obligation attaches to the prescriber and, through the coordinator, to the pharmacy involved. The pathway is available in most of the countries we serve, with variation in the specific documentation and timelines.

The personal-importation pathway

Personal importation is a pathway in which an individual patient, or a family member on the patient's behalf, imports a small quantity of a medicine for the patient's own use, typically under a limited personal-use exemption in the destination country's import regulations. The pathway is less structured, and the specifics vary significantly by country. In some destinations, personal importation is openly permitted for small quantities with a valid foreign prescription; in others it is conditionally permitted with notification to customs; in others it is permitted but with specific restrictions on the categories of medicine that qualify; in others still it is effectively closed. The pathway is typically patient-initiated rather than prescriber-led, and it usually does not involve a receiving hospital pharmacy or a documented receiving inspection.

How the two pathways actually differ

The first difference is who drives the pathway. A named-patient program is prescriber-led and regulator-authorized; personal importation is patient-initiated and, in most countries, operates under a blanket exemption rather than a case-specific authorization. The second difference is the volume and the purpose. NPPs accommodate full-course specialty therapies, multi-cycle regimens, gene and cell therapies, and institutional administration; personal importation is typically limited to small quantities for individual maintenance use. The third difference is the chain of custody. An NPP through a coordinator like us moves under a DSCSA-serialized transaction record via US-licensed specialty supply to a receiving institution with a documented receiving protocol; personal importation often moves through commercial parcel channels without the same documentation standard. The fourth difference is the regulatory status at destination. An NPP is specifically authorized for the drug-indication-patient combination; personal importation relies on a general exemption and carries different audit exposure for the patient and for the receiving environment. The fifth difference is the pharmacovigilance posture. An NPP coordinated through a licensed chain of custody has a defined pharmacovigilance channel; personal importation typically does not.

Pros of the named-patient pathway

The named-patient pathway produces a case that is structured from beginning to end: regulatory authorization on the front, documented chain of custody through the middle, and prescriber-led administration and follow-up on the back. It is appropriate for specialty therapies requiring cold-chain handling, for therapies requiring institutional administration, for therapies under multi-cycle regimens, and for cases where the prescriber or the receiving institution wants a full audit trail. It produces documentation that a destination regulator, an accreditation body, or a later adverse-event investigation can use. It is the pathway we operate under, and it is the pathway we recommend for the cases we take.

Pros of personal importation

Personal importation is simpler and faster for cases that fit its scope. A patient stabilized on a small-molecule oral therapy that is not locally available, where a one-to-three-month personal supply is appropriate and a blanket exemption in the destination country applies, can often import effectively with a valid foreign prescription and minimal administrative overhead. The pathway is particularly useful for long-distance maintenance therapy where the patient has established a relationship with a foreign prescriber and the destination country is one of those that clearly permits the route.

Cons of the named-patient pathway

The pathway carries more paperwork than personal importation and takes longer end to end, particularly for cases that are new to the specific destination country. It requires a prescriber willing to act as the pathway's clinical anchor. It costs more, because the coordination envelope is broader. For cases that fit personal importation well, an NPP is over-engineered.

Cons of personal importation

The pathway is fragile. A change in the destination country's import regulations can close the route on short notice, leaving a patient stranded mid-course. The chain of custody is weaker, which matters more for specialty biologics than for generic small molecules. The pharmacovigilance posture is thin, which matters when the patient experiences an adverse event and needs the event to be linkable to a specific lot and a specific supplier. The volume limits of personal importation are incompatible with many specialty therapies, particularly those requiring multi-cycle institutional administration. And the pathway puts more of the regulatory burden on the individual patient than is typically appropriate in a specialty-tier case.

Why we operate NPP-only

We are a specialty pharmacy operating at a concierge tier for specialty therapies that typically require cold-chain handling, institutional administration, and a documented pharmacovigilance channel. The named-patient pathway is the right structural fit for every one of those attributes, and it is the pathway that our sourcing, clinical review, and regulatory review are all built around. Personal importation is a legitimate pathway for the cases it fits, and we are happy to explain its mechanics to a family asking about it, but it is not a pathway we operate. For families considering it, the first conversation should be with the treating prescriber and, where needed, with a local customs-and-health-authority adviser in the destination country.

How to decide

A family considering either pathway should ask four questions. First, what is the therapy and what is the pack size the case requires. Second, is the destination country one where the named-patient pathway is clearly available for the indication in question. Third, does the prescriber want a documented chain of custody and an institutional receiving protocol. Fourth, is the case a one-off or a recurring regimen. If the answers point to specialty biologics, institutional administration, and a recurring regimen in a country with a recognizable NPP pathway, an NPP through a qualified coordinator is almost always the better path. If the answers point to a small maintenance supply of a stable oral therapy in a country with an open personal-importation route, the simpler pathway may be adequate. The honest answer is that most of our cases fall clearly in the first category, which is why we built the business around it.

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.